Long-term effects of recombinant human GH replacement in adults with GH deficiency: A systematic review

European Journal of Endocrinology

Volumn 169, Issue 1, 2013, Pages

  Appelman Dijkstra, Natasha M ^a   Claessen, Kim M J A ^a   Roelfsema, Ferdinand ^a   Pereira, Alberto M ^a   Biermasz, Nienke R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LIPID; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ANGINA PECTORIS; ANTHROPOMETRIC PARAMETERS; ARTERIAL WALL THICKNESS; BIOCHEMISTRY; BLADDER CARCINOMA; BODY COMPOSITION; BONE DENSITY; BONE METABOLISM; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM TUMOR; CHRONIC LYMPHATIC LEUKEMIA; COLON CARCINOMA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HEART INFARCTION; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHYSIS TUMOR; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; KIDNEY CARCINOMA; LIPID BLOOD LEVEL; LIPID METABOLISM; LONG TERM CARE; LUNG CARCINOMA; LUNG EMBOLISM; METABOLIC SYNDROME X; MORTALITY; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN;

ADULT; BLOOD GLUCOSE; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CAROTID INTIMA-MEDIA THICKNESS; HUMAN GROWTH HORMONE; HUMANS; LIPID METABOLISM; MORTALITY; MUSCLE STRENGTH; QUALITY OF LIFE; RECOMBINANT PROTEINS; RISK ASSESSMENT;

EID: 84879937786     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-1088     Document Type: Review

References (50)

1. Rosen T &Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 336 285-288. (doi:10.1016/0140-6736(90) 91812-O)
2. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC &Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001 357 425-431. (doi:10.1016/S0140-6736(00)04006-X)
3. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B &Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. Journal of Clinical Endocrinology and Metabolism 2004 89 2192-2199. (doi:10.1210/jc.2003-030840)
4. Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G &Svensson J. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. European Journal of Endocrinology 2012 166 787-795. (doi:10.1530/EJE-11-1072)
5. Koltowska-Häggström M, Mattsson AF, Monson JP, Kind P, Badia X, Casanueva FF, Busschbach J, Koppeschaar HP &Johannsson G. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? European Journal of Endocrinology 2006 155 109-119. (doi:10. 1530/eje.1.02176)
6. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G &Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. Journal of Clinical Endocrinology and Metabolism 2007 92 1442-1445. (doi:10. 1210/jc.2006-1487)
7. van der Klaauw AA, Romijn JA, Biermasz NR, Smit JW, van Doorn J, Dekkers OM, Roelfsema F &Pereira AM. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. European Journal of Endocrinology 2006 155 701-708. (doi:10.1530/eje.1.02283)
8. Biermasz NR, Hamdy NA, Pereira AM, Romijn JA &Roelfsema F. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clinical Endocrinology 2004 60 568-575. (doi:10.1111/j.1365-2265.2004.02021.x)
9. Götherström G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B &Johannsson G. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. Journal of Clinical Endocrinology and Metabolism 2001 86 4657-4665. (doi:10.1210/jc.86.10.4657)
10. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G &Svensson J. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. European Journal of Endocrinology 2007 156 55-64. (doi:10.1530/ eje.1.02317)
11. van Bunderen CC, van Nieuwpoort IC, Arwert LI, Heymans MW, Franken AA, Koppeschaar HP, van der Lely AJ &Drent ML. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. Journal of Clinical Endocrinology and Metabolism 2011 96 3151-3159. (doi:10.1210/jc.2011- 1215)
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC &Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Journal of Clinical Epidemiology 2008 61 344-349. (doi:10.1016/j.jclinepi.2007.11.008)
13. Gotherstrom G, Bengtsson BA, Sunnerhagen KS, Johannsson G &Svensson J. The effects of five-year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. Clinical Endocrinology 2005 62 105-113. (doi:10.1111/j.1365- 2265.2004.02181.x)
14. Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, Bengtsson BA, Johannsson G &Svensson J. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 2009 94 809-816. (doi:10.1210/jc.2008-1538)
15. Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, Bengtsson BA, Johannsson G &Svensson J. Muscle strength in elderly adults with GH deficiency after 10 years of GH replacement. European Journal of Endocrinology 2010 163 207-215. (doi:10.1530/EJE-10-0009)
16. Svensson J, Sunnerhagen KS &Johannsson G. Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength. Journal of Clinical Endocrinology and Metabolism 2003 88 2061-2069. (doi:10.1210/jc.2002-020901)
17. Gaillard RC, Mattsson AF, Akerblad AC, Bengtsson BA , Cara J, Feldt-Rasmussen U, Koltowska-Häggström M, Monson JP, Saller B, Wilton P et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. European Journal of Endocrinology 2012 166 1069-1077. (doi:10.1530/EJE-11-1028)
18. Clanget C, Seck T, Hinke V, Wuster C, Ziegler R &Pfeilschifter J. Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clinical Endocrinology 2001 55 93-99. (doi:10.1046/j.1365- 2265.2001.01284.x)
19. Giavoli C, Porretti S, Ronchi CL, Cappiello V, Ferrante E, Orsi E, Arosio M &Beck-Peccoz P. Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. Metabolism 2004 53 740-743. (doi:10.1016/j.metabol.2003.11.025)
20. Svensson J, Fowelin J, Landin K, Bengtsson BA &Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 2002 87 2121-2127. (doi:10.1210/jc.87.5. 2121)
21. Svensson J, Bengtsson BA, Rosen T, Oden A &Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 2004 89 3306-3312. (doi:10.1210/jc.2003-031601)
22. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, Lockhart S, Burnand KG, Salomon F, Sonksen PH et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 1999 84 2596-2602. (doi:10.1210/jc.84.8. 2596)
23. Spielhagen C, Schwahn C, Möller K, Friedrich N, Kohlmann T, Moock J, Ko?towska-Häggström M, Nauck M, Buchfelder M &Wallaschofski H. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Hormone &IGF Research 2011 21 1-10. (doi:10.1016/j.ghir.2010.10.005)
24. Gilchrist FJ, Murray RD &Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clinical Endocrinology 2002 57 363-370. (doi:10.1046/j.1365- 2265.2002.01608.x)
25. Roemmler J, Kuenkler M, Schneider HJ, Dieterle C &Schopohl J. Comparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replacement. Metabolism 2010 59 350-358. (doi:10.1016/j.metabol.2009.08.002)
26. Cenci MC, Conceicao FL, Soares DV, Spina LD, Brasil RR, Lobo PM, Michmacher E &Vaisman M. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults. Metabolism 2008 57 121-129. (doi:10. 1016/j.metabol.2007.08.015)
27. Chrisoulidou A, Beshyah SA, Rutherford O, Spinks TJ, Mayet J, Kyd P, Anyaoku V, Haida A, Ariff B, Murphy M et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism 2000 85 3762-3769. (doi:10.1210/jc.85.10.3762)
28. van der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW, Roelfsema F, Corssmit EP, Pijl H, Romijn JA &Pereira AM. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. European Journal of Endocrinology 2007 156 455-462. (doi:10.1530/EJE-06-0699)
29. Henche SA, Torres RR &Pellico LG. An evaluation of patterns of change in total and regional body fat mass in healthy Spanish subjects using dual-energy X-ray absorptiometry (DXA). European Journal of Clinical Nutrition 2008 62 1440-1448. (doi:10.1038/sj. ejcn.1602883)
30. Salomon F, Cuneo RC, Hesp R &Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New England Journal of Medicine 1989 321 1797-1803. (doi:10.1056/NEJM198912283212605)
31. Moller J, Jorgensen JO, Moller N, Hansen KW, Pedersen EB &Christiansen JS. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. Journal of Clinical Endocrinology and Metabolism 1991 72 768-772. (doi:10.1210/jcem-72-4-768)
32. Moller J, Moller N, Frandsen E, Wolthers T, Jorgensen JO &Christiansen JS. Blockade of the renin-angiotensin-aldosterone system prevents growth hormone-induced fluid retention in humans. American Journal of Physiology 1997 272 E803-E808.
33. Janssen YJ, Deurenberg P &Roelfsema F. Using dilution techniques and multifrequency bioelectrical impedance to assess both total body water and extracellular water at baseline and during recombinant human growth hormone (GH) treatment in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 1997 82 3349-3355. (doi:10.1210/jc.82.10.3349)
34. Netelenbos JC, Lems WF, Geusens PP, Verhaar HJ, Boermans AJ, Boomsma MM, Mulder PG &Papapoulos SE. Spine radiographs to improve the identification of women at high risk for fractures. Osteoporosis International 2009 20 1347-1352. (doi:10.1007/ s00198-008-0801-1)
35. Holmer H, Svensson J, Rylander L, Johannsson G, Rosén T, Bengtsson BA, Thorén M, Höybye C, Degerblad M, Bramnert M et al. Fracture incidence in GH-deficient patients on complete hormone replacement including GH. Journal of Bone and Mineral Research 2007 22 1842-1850. (doi:10.1359/jbmr. 070811)
36. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N &Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Annals of Internal Medicine 2000 133 111-122. (doi:10.7326/0003-4819-133-2-200007180-00010)
37. Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T &Lippe B. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. Journal of Clinical Endocrinology and Metabolism 2005 90 6431-6440. (doi:10.1210/jc.2005-0928)
38. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T &Lippe B. Long-term safety of recombinant human growth hormone in children. Journal of Clinical Endocrinology and Metabolism 2010 95 167-177. (doi:10.1210/jc.2009- 0178)
39. Ogilvy-Stuart AL &Gleeson H. Cancer risk following growth hormone use in childhood: implications for current practice. Drug Safety 2004 27 369-382. (doi:10.2165/00002018-200427060- 00002)
40. Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G &Hokken-Koelega A. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. Journal of Clinical Endocrinology and Metabolism 2012 97 E213-E217. (doi:10.1210/jc.2011-2882)
41. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y &Robison LL. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. Journal ofClinicalEndocrinology andMetabolism2002873136- 3141. (doi:10.1210/jc.87.7.3136)
42. Taback SP &Dean HJ. Mortality in Canadian children with growth hormone (GH) deficiency receiving GH therapy 1967-1992. The Canadian Growth Hormone Advisory Committee. Journal of Clinical Endocrinology and Metabolism 1996 81 1693-1696. (doi:10.1210/jc.81.5.1693)
43. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G &Coste J. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. Journal of Clinical Endocrinology and Metabolism 2012 97 416-425. (doi:10.1210/jc.2011-1995)
44. Swerdlow AJ, Higgins CD, Adlard P &Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002 360 273-277. (doi:10. 1016/S0140-6736(02)09519-3)
45. Burgers AM, Biermasz NR, Schoones JW, Pereira AM, Renehan AG, Zwahlen M, Egger M &Dekkers OM. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. Journal of Clinical Endocrinology and Metabolism 2011 96 2912-2920. (doi:10.1210/jc.2011- 1377)
46. Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG, Fitzgerald G, Jackson EA &Eagle KA. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart 2009 95 20-26. (doi:10.1136/hrt.2007. 138537)
47. Ettinger WH,Wahl PW, Kuller LH, Bush TL, Tracy RP, Manolio TA, Borhani NO, Wong ND &O'Leary DH. Lipoprotein lipids in older people. Results from the Cardiovascular Health Study. The CHS Collaborative Research Group. Circulation 1992 86 858-869. (doi:10.1161/01.CIR.86.3.858)
48. Nooyens AC, Visscher TL, Verschuren WM, Schuit AJ, Boshuizen HC, van Mechelen W &Seidell JC. Age, period and cohort effects on body weight and body mass index in adults: The Doetinchem Cohort Study. Public Health Nutrition 2009 12 862-870. (doi:10.1017/S1368980008003091)
49. Franklin SS, Gustin W IV, Wong ND, Larson MG, Weber MA, Kannel WB &Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997 96 308-315. (doi:10.1161/01.CIR.96.1. 308)
50. Kreitschmann-Andermahr I, Siegel S, Francis F, Buchfelder M, Schneider HJ, Kann PH,Wallaschofski H, Koltowska-HäggströmM &Brabant G. Variation of the baseline characteristics and treatment parameters over time: an analysis of 15 years of growth hormone replacement in adults in the German KIMS database. Pituitary 2012 15 (Suppl 1) S72-S80. (doi:10.1007/s11102- 012-0410-z)